Celsion Announces Completion of OVATION Study and Provides Update on its Immunotherapy Trial in Advanced … – Nasdaq
|
Celsion Announces Completion of OVATION Study and Provides Update on its Immunotherapy Trial in Advanced …
Nasdaq LAWRENCEVILLE, N.J., July 05, 2017 (GLOBE NEWSWIRE) — Celsion Corporation (NASDAQ:CLSN) today provided an update on its Phase Ib dose escalating clinical trial (the OVATION Study) combining GEN-1, the Company's IL-12 gene-mediated … |
